A proof of concept study on real-time LiMAx CYP1A2 liver function assessment of donor grafts during normothermic machine perfusion.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 08 07 2021
accepted: 08 11 2021
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 28 1 2022
Statut: epublish

Résumé

No single reliable parameter exists to assess liver graft function of extended criteria donors during ex-vivo normothermic machine perfusion (NMP). The liver maximum capacity (LiMAx) test is a clinically validated cytochromal breath test, measuring liver function based on 13CO2 production. As an innovative concept, we aimed to integrate the LiMAx breath test with NMP to assess organ function. Eleven human livers were perfused using NMP. After one hour of stabilization, LiMAx testing was performed. Injury markers (ALT, AST, miR-122, FMN, and Suzuki-score) and lactate clearance were measured and related to LiMAx values. LiMAx values ranged between 111 and 1838 µg/kg/h, and performing consecutive LiMAx tests during longer NMP was feasible. No correlation was found between LiMAx value and miR-122 and FMN levels in the perfusate. However, a significant inverse correlation was found between LiMAx value and histological injury (Suzuki-score, R = - 0.874, P < 0.001), AST (R = - 0.812, P = 0.004) and ALT (R = - 0.687, P = 0.028). Furthermore, a significant correlation was found with lactate clearance (R = 0.683, P = 0.043). We demonstrate, as proof of principle, that liver function during NMP can be quantified using the LiMAx test, illustrating a positive correlation with traditional injury markers. This new breath-test application separates livers with adequate cytochromal liver function from inadequate ones and may support decision-making in the safe utilization of extended criteria donor grafts.

Identifiants

pubmed: 34873187
doi: 10.1038/s41598-021-02641-0
pii: 10.1038/s41598-021-02641-0
pmc: PMC8648778
doi:

Substances chimiques

Lactic Acid 33X04XA5AT
CYP1A2 protein, human EC 1.14.14.1
Cytochrome P-450 CYP1A2 EC 1.14.14.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

23444

Informations de copyright

© 2021. The Author(s).

Références

Crit Care. 2013 Oct 31;17(5):R259
pubmed: 24172237
Nat Commun. 2020 Jun 16;11(1):2939
pubmed: 32546694
J Pediatr. 1978 Jul;93(1):62-6
pubmed: 650346
J Gastroenterol Hepatol. 2017 Mar;32(3):701-707
pubmed: 22554202
Ann Surg. 2019 Nov;270(5):906-914
pubmed: 31633615
Liver Transpl. 2010 Feb;16(2):172-80
pubmed: 20104485
Am J Transplant. 2018 Aug;18(8):2005-2020
pubmed: 29419931
Lancet. 2002 Oct 12;360(9340):1155-62
pubmed: 12387968
Ann Surg. 2009 Jul;250(1):119-25
pubmed: 19561474
Liver Transpl. 2016 Aug;22(8):1129-35
pubmed: 27081833
Artif Organs. 2016 Jul;40(7):692-8
pubmed: 26527580
PLoS One. 2014 Nov 04;9(11):e110642
pubmed: 25369327
World J Gastroenterol. 2006 Apr 14;12(14):2217-22
pubmed: 16610024
Liver Transpl. 2019 Mar;25(3):488-499
pubmed: 30817859
Liver Transpl. 2016 Feb;22(2):226-36
pubmed: 26359934
J Hepatol. 2014 Sep;61(3):672-84
pubmed: 24798616
J Gastrointest Surg. 2015 Sep;19(9):1713-24
pubmed: 25917535
J Breath Res. 2017 Nov 29;12(1):016005
pubmed: 28742055
Ann Surg. 2019 Nov;270(5):783-790
pubmed: 31592808
J Hepatobiliary Pancreat Surg. 2005;12(1):16-22
pubmed: 15754094
J Invest Surg. 2015 Feb;28(1):24-31
pubmed: 25394215
Arch Toxicol. 2020 Feb;94(2):401-415
pubmed: 32020249
Transplantation. 2008 Oct 15;86(7):941-6
pubmed: 18852660
Transplantation. 2020 Aug;104(8):1604-1611
pubmed: 32732837
J Gastroenterol Hepatol. 2012 Mar;27(3):540-6
pubmed: 21777274
Am J Clin Nutr. 2010 Dec;92(6):1369-77
pubmed: 20962155
Nature. 2018 May;557(7703):50-56
pubmed: 29670285
Liver Transpl. 2010 Jul;16(7):874-84
pubmed: 20583086
Updates Surg. 2020 Dec;72(4):925-938
pubmed: 32749596
Clin Liver Dis. 2017 May;21(2):289-301
pubmed: 28364814
Mol Med. 2016 Mar;21(1):833-846
pubmed: 26552060

Auteurs

Ivo J Schurink (IJ)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Jubi E de Haan (JE)

Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Jorke Willemse (J)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Matteo Mueller (M)

Department of Surgery, University Hospital of Zürich, Zürich, Switzerland.

Michael Doukas (M)

Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Henk Roest (H)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Femke H C de Goeij (FHC)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Wojciech G Polak (WG)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Jan N M Ijzermans (JNM)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Philipp Dutkowski (P)

Department of Surgery, University Hospital of Zürich, Zürich, Switzerland.

Luc J W van der Laan (LJW)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.

Jeroen de Jonge (J)

Division of Hepatopancreatobiliary Surgery, Department of Surgery, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. j.dejonge.1@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH